The maximum standardized uptake value of 18 F-FDG PET scan to determine prognosis of hormone-receptor positive metastatic breast cancer.
BACKGROUND
Whether PET scan maximum standard uptake value (SUVmax) could differentiate luminal A from luminal B and help predict the survival of metastatic breast cancer (MBC) patients with luminal subtype is still unknown and need to be investigated.


METHODS
305 MBC patients with luminal subtypes were screened with PET/CT. Eligible patients were prospectively followed up.


RESULTS
In total, 134 patients were eligible for this study. SUVmax was significantly related to the number of metastatic sites and presence of visceral metastasis on univariate analysis. SUVmax could not effectively differentiate patients with luminal A from luminal B subtype. Although luminal subtype at diagnosis could predict the relapse-free interval, it could not predict progression-free survival (PFS) or overall survival (OS) after developing relapse. In contrast, SUVmax was predictive of both PFS and OS and this effect was maintained in multivariate COX regression model.


CONCLUSIONS
SUVmax of MBC did not correlate with molecular subtypes of primary tumor. While molecular subtype may be a valuable prognostic factor at primary diagnosis of breast cancer, the SUVmax, rather than molecular subtype, does have a potential to predict independently in multivariate analysis for the PFS and OS in patients with metastatic disease of luminal subtype.
Department of Medical Oncology, Department of Oncology, Fudan University Shanghai Cancer Center; Shanghai Medical College, Fudan University, Shanghai, China.
Jian
J
Zhang
Zhen
Z
Jia
Joseph
J
Ragaz
Ying-Jian
YJ
Zhang
Min
M
Zhou
Yong-Ping
YP
Zhang
Gang
G
Li
Bi-Yun
BY
Wang
Zhong-Hua
ZH
Wang
Xi-Chun
XC
Hu
D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000473:pathology; D018572:Disease-Free Survival; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics; D006801:Humans; D008207:Lymphatic Metastasis; D008875:Middle Aged; D049268:Positron-Emission Tomography / Q000379:methods; D011237:Predictive Value of Tests; D011379:Prognosis; D016016:Proportional Hazards Models; D011446:Prospective Studies; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism
D019275:Radiopharmaceuticals; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D019788:Fluorodeoxyglucose F18